Amylyx Pharmaceuticals recorded significant progress in Q3 2025, highlighted by the continued advancement of its lead drug avexitide for post-bariatric hypoglycemia, while strengthening its financial position with a cash balance of $344 million.

• Avexitide, granted FDA breakthrough therapy designation, aims to address the unmet need in post-bariatric hypoglycemia with a pivotal Phase III trial set to complete recruitment by Q1 2026.
• Cash position strengthened to $344 million following a successful public offering, positioning the company for a potential drug launch in 2027.
• Positive participant engagement and motivation reported in clinical trials, reinforcing the significant demand for effective treatment options.
• AMX0035 for Wolfram syndrome and AMX0114 for ALS remain on track, with pivotal study plans and preliminary data expected in the coming year.